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Rapid and accurate diagnosis of sepsis remains clinically challenging. The lack of specific 34 
biomarkers that can differentiate sepsis from non-infectious systemic inflammatory diseases 35 
often leads to excessive antibiotic treatment. Novel diagnostic tests are urgently needed to 36 
rapidly and accurately diagnose sepsis and enable effective treatment. Despite investment on 37 
cutting-edge technologies available today, the discovery of disease-specific biomarkers in blood 38 
remains extremely difficult. The highly dynamic environment of blood restricts access to vital 39 
diagnostic information that can be obtained by proteomic analysis. Here, we employed clinically 40 
used lipid-based nanoparticles (AmBisome®) as an enrichment platform to analyze the human 41 
plasma proteome in the setting of sepsis. We exploited the spontaneous interaction of plasma 42 
proteins with nanoparticles (NPs) once in contact, called the ‘protein corona’, to discover 43 
previously unknown disease-specific biomarkers for sepsis diagnosis. Plasma samples obtained 44 
from non-infectious acute systemic inflammation controls and sepsis patients were incubated ex 45 
vivo with AmBisome® liposomes, and the resultant protein coronas were thoroughly 46 
characterised and compared by mass spectrometry (MS)-based proteomics. Our results 47 
demonstrate that the proposed nanoparticle enrichment technology enabled the discovery of 67 48 
potential biomarker proteins that could reproducibly differentiate non-infectious acute systemic 49 
inflammation from sepsis. This study provides proof-of-concept evidence that nanoscale-based 50 
‘omics’ enrichment technologies have the potential to substantially improve plasma proteomics 51 
analysis and to uncover novel biomarkers in a challenging clinical setting. 52 
 53 

















Sepsis is defined as a life-threatening organ dysfunction triggered by a dysregulated 69 
immune response to an infection.1 It is a leading cause of mortality, accounting for more than six 70 
million deaths each year worldwide.2 Delays in diagnosing sepsis and initiating appropriate 71 
antimicrobial treatments are associated with higher mortality.3 Hence, there is an unmet need for 72 
the development of biomarkers to rapidly diagnose sepsis and monitor its progression. 73 
A significant challenge in the clinical setting is the diagnostic uncertainty in differentiating 74 
patients with sepsis in a highly heterogeneous, critically ill patient population. Microbiological 75 
cultures are the current gold standard for identifying causative pathogen phenotypes and guiding 76 
antimicrobial treatment,4 however they are limited by a lack of sensitivity and by long incubation 77 
times (up to 72 hours).5 Given the high mortality rate associated with delayed treatments and the 78 
lack of specific diagnostic tools, broad-spectrum antimicrobial treatment is recommended in all 79 
patients suspected of developing sepsis.6 As a result, broad-spectrum antimicrobials are 80 
frequently administered to patients with acute sterile inflammation or viral infections, contributing 81 
to the emergence and propagation of antimicrobial resistant pathogens.7 Blood-circulating C-82 
reactive protein and procalcitonin biomarkers are increasingly used in routine clinical practice to 83 
help identify unwell patients,8, 9 yet they lack diagnostic specificity as they are known to be 84 
upregulated in other acute inflammatory disorders.10, 11 85 
Considering the complexity of the sepsis syndrome and the molecular pathways 86 
underlying immune responses that can also arise from non-infectious diseases,12 the use of a 87 
single diagnostic biomarker is unlikely to offer the required specificity and sensitivity.13 To date, 88 
the lack of protein biomarkers or biomarker combinations to identify sepsis is partially attributed 89 
to the incapacity of currently available proteomics platforms to offer an in-depth analysis of the 90 
plasma proteome.14  91 
Although nanotechnology-based platforms have been developed to enable the 92 
quantification of specific blood molecules, ongoing efforts are focusing on the discovery of 93 
previously undetectable disease-specific biomarkers.15 We have previously exploited the 94 
spontaneous interaction of intravenously administered nanoparticles with proteins, named the 95 
‘protein corona’,16, 17 to capture and amplify low molecular weight and low abundant proteins 96 
from the blood circulation of tumour-bearing mice and ovarian carcinoma patients.18, 19 The 97 
protein corona formed around intravenously injected clinically-used liposomes was found to be 98 
enriched with disease-specific proteins which could not be detected by conventional plasma 99 
proteomic analysis. The elimination of background, highly abundant proteins and the 100 
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identification of only the nanoparticle-bound proteins make this nano-platform technology very 101 
promising for the discovery of novel diagnostic biomarkers and more studies are needed to 102 
explore the prospective applications. 103 
In the present study, we aimed at further exploring the potential use of the proposed 104 
nano-scavenger tool in the highly complex clinical challenge of differentiating sepsis from non-105 
infectious acute systemic inflammation in humans. The occurrence of activated systemic 106 
inflammation pathways in both conditions adds another level of complexity in comparison to our 107 
previous work focusing on the discovery of cancer biomarkers.18 To prove our hypothesis, we 108 
incubated the commercially available amphotericin B-containing liposomes (AmBisome®), 109 
clinically used to treat serious, life-threatening fungal infections,20 with plasma samples obtained 110 
from patients with confirmed sepsis and from phenotypically similar sterile tissue injury patients 111 
with systemic inflammatory response syndrome (SIRS) (Figure 1A). We chose AmBisome® as 112 
the preferred liposomal formulation because of its clinical use in high-risk patients with 113 
suspected sepsis (most notably in the setting of immunosuppression in hematological oncology, 114 
cell and tissue transplantation).20 Our results demonstrated that comprehensive comparison of 115 
the resultant protein coronas led to the identification of 67 potential biomarker proteins that could 116 
reproducibly distinguish non-infectious acute systemic inflammation from sepsis.  117 
 118 
Results  119 
 120 
Physicochemical characterisation of bare and corona-coated Amphotericin B-intercalated 121 
liposomes (AmBisome®). Amphotericin B-intercalated liposomes (AmBisome®) were 122 
physicochemically and structurally characterised prior to and after their ex vivo incubation with 123 
human plasma samples obtained from SIRS control group (n=7) and sepsis patients (n=12). 124 
Patient clinical characteristics and blood cell culture results are summarized in Tables S1 and 125 
S2. Liposomes were also incubated with plasma obtained from healthy donors (n=12) as a 126 
control. AmBisome® liposomes were allowed to interact with human plasma proteins for 1 hour 127 
followed by a two-step purification protocol, for the separation of corona-coated liposomes from 128 
unbound and weakly bound plasma proteins, as we have previously described.18, 19, 21, 22  129 
Dynamic light scattering (DLS) and negative stain transmission electron microscopy 130 
(TEM) were conducted before and after the ex vivo incubation of liposomes with human plasma 131 
to assess their physicochemical properties prior to and after corona formation (Figures 1B, S1 132 
and 1C). The physicochemical characteristics of the commercially available liposomal 133 
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formulation AmBisome® employed in this study are summarized in Figure 1B. Bare liposomes 134 
displayed a mean hydrodynamic diameter of 102.6 nm, a negative surface charge of -54.3 mV 135 
and low polydispersity index values (0.093) indicating a narrow size distribution (Figure 1B). 136 
TEM imaging revealed a well-dispersed liposomal population with a homogenous size 137 
distribution correlating that of DLS measurements (Figure 1C). 138 
Dynamic light scattering measurements of corona-coated AmBisome® liposomes 139 
demonstrated that their size was not significantly affected upon corona formation, while their 140 
surface charge was shifted towards less negative values (Figures 1B and 1S, Table S3) 141 
indicating their interaction with protein molecules. TEM confirmed the presence of protein 142 
molecules onto the surface of AmBisome® liposomes and revealed that the recovered corona-143 
coated liposomes remained intact post-incubation with human plasma and purification, showing 144 
no structural differences compared to the bare NP (Figure 1C).  145 
 146 
Quantitative and qualitative comparison of the ex vivo protein coronas formed onto 147 
AmBisome® liposomes. To quantitatively compare the total amount of protein adhered onto 148 
AmBisome® liposomes in the three different conditions under investigation, we calculated the 149 
protein binding value (Pb), expressed as the amount of proteins in μg per each μmole of lipid. As 150 
shown in Figure 2A, the total amount of proteins adsorbed onto liposomes after their incubation 151 
with plasma samples obtained from sepsis patients was significantly higher compared to the 152 
amount of proteins adsorbed onto liposomes after their incubation with plasma samples 153 
obtained from healthy volunteers (** indicates p<0.01 (p=0.0068) using the non-parametric 154 
Kruskal-Wallis test). This clearly indicates that the formation of protein corona onto AmBisome® 155 
liposomes is quantitatively influenced by human sepsis condition. This observation is in 156 
agreement with our previous studies, showing that the total amount of protein molecules 157 
adsorbed onto the NPs surface is determined by the presence or absence of tumorigenesis, 158 
reflecting thus the ongoing pathophysiological alterations in blood proteome.18 159 
Interestingly, the average Pb values observed post-incubation of AmBisome® liposomes 160 
with plasma samples obtained from SIRS patients was similar to that of sepsis patients. This 161 
reflects the clinical challenge in differentiating sepsis from other non-infectious events, such as 162 
acute trauma and burns. As shown in Figure 2A, the SIRS group exhibited greater variations 163 
among the individual patients Pb values compared with the healthy controls and the sepsis 164 
patients group. This was expected considering that SIRS patients suffered from a wide range of 165 
acute inflammation-related pathological conditions other than infection. It is worth mentioning 166 
that the total amount of protein adsorbed onto the surface of AmBisome® liposomes was higher 167 
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compared to what we have previously observed for PEGylated doxorubicin-encapsulated 168 
liposomes (Caelyx®) of similar size.19 This is in agreement with the literature suggesting that 169 
non-PEGylated surfaces tend to adsorb a higher amount of proteins once in contact with 170 
biological fluids.23 171 
To investigate whether the higher amount of protein adsorbed onto AmBisome® 172 
liposomes could offer a comprehensive coverage of the plasma proteome, corona proteins 173 
associated with liposomes were separated by SDS-PAGE and visualized by Imperial Protein 174 
stain, as illustrated in Figure 2B. The elimination of highly abundant proteins allowed the 175 
enrichment of the low MW blood proteome, as we have previously reported (Figure 2B).18, 19, 22 176 
Distinct protein bands were profiled in the case of corona samples, while the protein pattern of 177 
plasma control verified the masking effect of albumin (Figure 2B). In agreement with the BCA 178 
assay data, the amount of protein adsorbed onto AmBisome® post-incubation with plasma 179 
obtained from sepsis patients was higher in comparison to the total amount adsorbed post-180 
incubation with plasma obtained from healthy volunteers. Similarly, the considerable variation in 181 
the total amount of liposome-bound protein (Figure 2A) was reflected in the corona profiles of 182 
SIRS patients (Figure 2B), indicating the high heterogeneity of this group.   183 
 184 
The NP protein corona-enabled biomarker discovery to differentiate sepsis from non-185 
infectious acute systemic inflammation. To identify potential biomarker proteins that can 186 
differentiate sepsis from non-infectious acute systemic inflammation, we comprehensively 187 
characterised and compared the resultant protein coronas by label-free liquid chromatography–188 
mass spectrometry (LC-MS/MS).  189 
Progenesis QI data analysis (version 3.0; Nonlinear Dynamics) enabled us to statistically 190 
compare the protein corona profiles of healthy controls, SIRS patients and sepsis patients. Raw 191 
data generated from LC-MS/MS analysis were processed and the mean normalized abundance 192 
of each group, the relative protein expression (fold-change) and the reliability of measured 193 
differences (ANOVA, p value) were calculated (Figure 3, Figure S2 and Tables 1, S4, S5 and 194 
S6). As shown in Figure S2 and Table S5, common proteins between the three different groups 195 
displayed quantitative differences and enhanced our hypothesis that proteomic analysis of the 196 
liposomal protein coronas unravels differences between healthy and diseased states. In order to 197 
identify differentially expressed proteins between healthy controls and the sepsis patients, we 198 
compared the protein patterns of the ex vivo formed coronas. Results were filtered to present a p 199 
value <0.05 and interestingly, n=135 proteins were found to be differentially expressed, of which 200 
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n=88 were upregulated and n=47 were downregulated in sepsis patients samples (Figure S2B 201 
and Table S6). 202 
Considering that the prevalent challenge in the clinic is to distinguish between sepsis and 203 
non-infectious acute systemic inflammation, we performed further analysis focused on the 204 
identification of differentially abundant proteins between SIRS controls and sepsis patients. As 205 
shown by the normalized abundance values of Figure 3A and Table S4, quantitative differences 206 
were observed between the two groups with n=67 proteins being differentially expressed (n=34 207 
upregulated; n=33 downregulated), (Figure 3B, Figure S3 and Table 1). Interestingly, the 208 
clinically-used CRP protein biomarker was not found to be differentially abundant between 209 
sepsis patients and SIRS controls (p value=0.29, max fold-change=1.97, Table 1 and S4), 210 
which is consistent with its acknowledged lack of diagnostic specificity.10 We also performed 211 
Principal Component Analysis (PCA) to assess whether these 67 identified on the surface of 212 
AmBisome® proteins were able to discriminate sepsis from SIRS. Strikingly, PCA analysis 213 
unveiled the formation of two distinct clusters (Figure S3). 214 
Ingenuity Pathway Analysis (IPA® QIAGEN Bioinformatics) was then performed to 215 
investigate if the corona proteins found to be differentially expressed between sepsis and SIRS 216 
groups (n=67) have been previously associated with bacterial sepsis and/or infection. Disease 217 
and function IPA search revealed the association of n=7 corona proteins with bacterial infection 218 
pathways (Figure 3C and Table S7): serum amyloid P component (APCS); B-cell 219 
lymphoma/leukemia 10 (BCL10), CD5 antigen like (CD5L), gamma-aminobutyric acid type A 220 
receptor alpha1 subunit (GABRA1), immunoglobulin heavy constant gamma 3 (IGHG3), 221 
immunoglobulin kappa variable 2-24 (IGKV2-24), lipopolysaccharide binding protein (LBP). 222 
However, none of the above differentially abundant proteins was previously described in the 223 
literature as a potential biomarker for sepsis.   224 
Noteworthy, serum amyloid P has been previously described to act as a pathogen 225 
recognition receptor due to its binding affinity towards microbial surface components.24-26 226 
Another study revealed the key role of APCS in complement-mediated immunity against 227 
Streptococcus pneumoniae, which suggests that APCS is a significant component of the innate 228 
immunity against this pathogen.27 In addition, B-cell lymphoma/leukemia 10 (BCL10) has been 229 
reported to induce the activation of lymphocytes,28, 29 as well as to be elevated following 230 
exposure of intestinal epithelial cells to LPS.30 Similar to APCS and BCL10, CD5 antigen like 231 
(CD5L) has been shown to be implicated in monocyte inflammatory pathways in response to the 232 
surface components of bacteria LPS and lipoteichoic acid (LTA).31 More interestingly, a recent 233 
clinical study has shown that CD5L serum levels of 150 sepsis patients were significantly more 234 
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elevated on the day of admission to intensive care unit (ICU) than the levels of PCT and CRP 235 
compared to ICU controls and healthy controls.32 As far as lipopolysaccharide binding protein 236 
(LBP) concerns, the results has been so far controversial. Some studies have reported a 237 
moderate to low diagnostic capacity for sepsis,33 while others demonstrated that LBP levels 238 
were significantly higher in 97% of sepsis patients than healthy controls.34 The presence of these 239 
proteins on the surface of liposomes suggests that the NP-protein corona mirrors the ongoing 240 
pathophysiological alterations in plasma.  241 
In order to provide some initial validation of the proteomic data obtained, we performed 242 
enzyme-linked immunosorbent assay (ELISA) experiments using plasma samples obtained from 243 
the same SIRS and sepsis patient groups. In agreement with our mass spectrometry data, 244 
ELISA experiments demonstrated that the amount of the clinically used biomarker CRP, was not 245 
significantly different between SIRS and sepsis groups (95% CI, AUC = 0.7619) (Figure S4). 246 
Interestingly, serum amyloid P (APCS) and cathepsin G (CTSG), identified in the corona 247 
samples obtained from SIRS and sepsis patients exhibited higher AUC values than CRP (95% 248 
CI, AUC = 0.7937 for APCS and 95% CI, 0=9048 for CTSG).  249 
Overall, we show that the use of a different from our previous studies18, 19 liposomal 250 
formulation, AmBisome®, facilitates the enrichment of complex biofluids with low abundant 251 
molecules, enabling thus the discovery of disease-specific biomarkers upon interaction with 252 
plasma proteins. The above data suggest that proteomic analysis of the NP coronas uncovers 253 
previously unknown potential biomarker proteins that can differentiate sepsis from non-infectious 254 
acute systemic inflammation with higher specificity and sensitivity than the clinically used 255 














There is an unmet need for the development of biomarkers to rapidly diagnose sepsis 268 
and monitor its progression. The complexity of sepsis pathology and the lack of accurate 269 
diagnostic tests impede early diagnosis which in turn impact on treatment decision-making.35  270 
Currently, diagnosis of sepsis relies on the time-consuming process of blood culturing, often 271 
associated with false negative results.4, 5 The diagnostic uncertainty in differentiating patients 272 
with sepsis from those suffering from non-infectious acute systemic inflammation makes sepsis 273 
the Achilles’ heel of health care.2 The clinically-used diagnostic and disease monitoring blood 274 
marker, C reactive protein (CRP) is an indicator of acute-phase responses and thus is unable to 275 
distinguish sepsis from other systemic inflammation-associated diseases.10, 11, 36 In addition, the 276 
clinical signs and symptoms of sepsis in its early stages mirror those of non-infectious acute 277 
systemic inflammation12 and this leads to antibiotics being administered to patients with acute 278 
sterile inflammation or viral infection. To date, there is no biomarker or any diagnostic test with 279 
the capacity to distinguish between sepsis and non-infectious acute systemic inflammation.37  280 
Currently available proteomic techniques are capable of sampling a relatively small 281 
fraction of the blood proteome which is mainly composed of highly abundant proteins. The 282 
signal-to-noise issue, mainly caused by the albumin and immunoglobulins restricts access to the 283 
vital diagnostic information that could be obtained.38-41 _ENREF_36Plasma immunodepletion 284 
and fractionation methods are predominantly employed to tackle this issue, however their 285 
extensive use leads to a significant loss of the low molecular plasma proteome along with the 286 
highly abundant plasma proteins.39, 42 MS-based proteomics have significantly aided to the 287 
discovery of several sepsis biomarkers and provided valuable information about the complex 288 
molecular mechanisms underlining this condition.43 However, to the best of our knowledge, there 289 
are only a few proteomic-based studies reporting the discovery of a single biomarker or a panel 290 
of biomarkers that can differentiate sepsis from non-infectious acute systemic inflammation.37, 44  291 
Even though there is an increasing evidence that nanoparticle-assisted discovery of 292 
novel biomarkers by high-throughput proteomics can revolutionise the field of diagnostics,18, 19 293 
nanoparticles have been so far utilised in the biomarker verification and validation phases to 294 
boost immunoassays sensitivities and detect already known biomarker molecules.45, 46 295 
Specifically in the case of sepsis, NPs have been successfully employed as contrast agents and 296 
biosensors47 to facilitate the detection of either already known protein biomarkers (CRP, PCT),48 297 
pathogenic DNA49-52 or bacterial cells53-56 by amplifying their signal and improving read-outs. 298 
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Among the emerging applications, the exploitation of the NP-protein corona for the discovery of 299 
novel biomarkers in conjunction with high-throughput proteomics, has been recently proposed 300 
by us17-19 and others.57, 58 In our previous work, we demonstrated that the spontaneous 301 
interaction of intravenously injected clinically-used liposomes with plasma proteins allowed the 302 
discovery of multiple proteins differentially abundant between healthy and tumour bearing 303 
mice.18 It should be emphasised that the proposed liposome-based technology facilitates the 304 
initial untargeted discovery step of the biomarker development pipeline and not the detection of 305 
a specific biomarker molecule for clinical diagnosis. 306 
In this study, we aimed to further explore and validate the use of the human ex vivo 307 
nanoparticle-protein corona for the discovery of previously undetectable sepsis biomarkers. To 308 
evaluate whether the human ex vivo protein corona could reveal differences in the complex case 309 
of differentiating between two diseased states, we thoroughly characterised and compared the 310 
protein corona patterns formed around the clinically-used Amphotericin B-intercalated liposomal 311 
formulation (AmBisome®), post-incubation with plasma obtained from healthy donours, SIRS 312 
patients and sepsis patients. 313 
Our results here are in agreement with our previous findings in tumour-bearing mice and 314 
humans,18, 19 showing that the protein corona changes both quantitatively (Figure 2A) and 315 
qualitatively (Figure 2B and Figure S2) in the presence or absence of the disease. A 316 
significantly higher total amount of protein was adsorbed onto the surface of liposomes after 317 
their incubation with plasma from sepsis in comparison with healthy controls (Figure 2A). The 318 
above differences in the protein corona patterns of healthy individuals compared with sepsis 319 
patients reinforce our hypothesis that the NP-protein corona mirrors the ongoing 320 
pathophysiological alterations in plasma proteome. Equally consistent with our previous 321 
observations18, 19 were the gel electrophoresis results, demonstrating that the AmBisome® 322 
protein corona is reproducibly enriched by low molecular weight proteins (Figure 2B), which 323 
conventional proteomics are unable to sensitively detect.  324 
Considering that sepsis pathology is a highly complex physiological process, there is a 325 
prevalent concord that a panel of multiple biomarkers, rather than a single biomarker will be 326 
needed for its accurate diagnosis.13, 59 The clinically challenging scenario of distinguishing non-327 
infectious acute systemic inflammation from sepsis,2 prompt us to investigate whether the NP-328 
protein corona platform can be utilised to identify biomarkers specific to sepsis. Comparative 329 
analysis between the protein corona fingerprints of SIRS controls and sepsis patients unveiled 330 
67 novel potential biomarkers, with n=34 and n=33 proteins being upregulated and 331 
downregulated in sepsis, respectively (Figures 3A, 3B, S3 and Table 1). Especially notable was 332 
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that the discovered corona proteins presented max fold-change and p values much higher than 333 
the clinically-used CRP protein biomarker. Indeed, CRP protein was not found to be differentially 334 
expressed between SIRS controls and sepsis patients (p value>0.05). This observation is 335 
consistent with the acknowledged lack of CRP diagnostic specificity10 and highlights the pressing 336 
need for new diagnostic biomarkers. PCA analysis of the 67 identified protein corona biomarkers 337 
revealed the formation of two distinct clusters, suggesting that these proteins can differentiate 338 
between the two diseased states (Figure S3). 339 
To date, there is not any clinically used biomarker that differentiates sepsis from non-340 
infectious acute inflammation. Even though, disease and function IPA search revealed the 341 
association of n=7 corona proteins with bacterial infection-related pathways (Figure 3C), none of 342 
the potential biomarker proteins discovered in this study (n=67) was found to be previously 343 
proposed for sepsis diagnosis. This suggests that the NP-corona platform can potentially unravel 344 
information about the human pathophysiology and the underlining mechanisms of human 345 
bacterial sepsis. ELISA validation experiments demonstrated that the corona proteins APCS and 346 
CTSG displayed greater sensitivity and specificity compared to the clinically-used biomarker 347 
CRP (Figure S4). More work is needed to examine the role of the above-identified proteins in 348 
bacterial sepsis and/or inflammation and their potential utility for the development of future 349 
diagnostic tests. 350 
In our previous work, we demonstrated that protein crorona analysis formed around 351 
Doxil® liposomes enriches the identification of low abundant and low MW proteins allowing an in 352 
depth analysis of the plasma proteome. [ref] Here, we explore the exploitation of protein corona 353 
or biomarker discovery in a much more clinically challenging scenario.  Our results reveal that 354 
analysis of protein corona formed around AmBisome® liposomes allows mining of the blood 355 
proteome and discovery of potential diagnostic biomarker panels in the presence of severe 356 
blood inflammatory responses. AmBisome® liposomes were found to harvest disease-specific 357 
molecules upon incubation with plasma, which paves the way towards further development of 358 
this technology by using different types of NPs. It is worth mentioning that this study focuses on 359 
the initial phase of biomarker discovery, which renders meticulous future exploration on the 360 
verification and validation phases of the biomarker development pipeline important, however out 361 
of the scope of this work. Clearly, further studies are needed using a higher number of human 362 
clinical samples to determine the specificity and sensitivity of the discovered biomarkers that can 363 
be used in the future as a meaningful and accurate panel in combination with clinical 364 







In this study, we describe the formation of protein corona around the clinically-used liposomal 370 
Amphotericin B formulation (AmBisome®). Our data reinforces our previous proposition to 371 
exploit the nanoparticle-biomolecule corona in order to allow in depth analysis of the blood 372 
proteome and to uncover potential biomarker proteins. To explore the adaptability of this nano-373 
scavenging tool to enrich disease-specific molecules with diagnostic potential in a more clinically 374 
challenging scenario, we molecularly compared the ex vivo coronas formed upon incubation of 375 
liposomes with plasma samples obtained from phenotypically identical non-infectious acute 376 
systemic inflammation patients and sepsis patients. Despite the similar inflammatory responses 377 
arisen in both conditions, proteomic comparison of the biomolecule coronas revealed 67 plasma 378 
proteins that could reproducibly differentiate sepsis from non-infectious acute systemic 379 
inflammation. The nanoparticle-corona platform has the potential to accelerate the development 380 
of panels of biomarkers that can in combination with clinical evaluation rapidly and accurately 381 




Ethical approvals of patient plasma samples. The patient samples were collected and stored at Salford 384 
Royal NHS Foundation Trust following review and approval by the NHS National Research Ethics Service 385 
Committee North West – Greater Manchester South (Ref#14/NW/1404). Sample collection from patients 386 
was undertaken by designated members from Salford Royal NHS Foundation Trust’s research and 387 
development team. All experiments were performed in compliance with the University of Manchester 388 
policy on human plasma use and ethics.  389 
 390 
Selection of patient samples. Suitable patient samples were identified via study case report forms. The 391 
selection of patient samples was based on the clinical criteria for acute systemic inflammation and the 392 
blood/urine culture results. For inclusion in the sepsis group, patients had to have blood culture evidence 393 
of bacterial infection and a score of 2 or more out of 4 criteria for acute systemic inflammation.1 For 394 
patients to be included in the non-infectious acute systemic inflammation group, they had to have 2 or 395 
more clinical criteria for acute systemic inflammation, no clinical or microbiological laboratory evidence of 396 
infection (negative blood/urine culture tests) and given no more than one dose of antibiotics. 397 
 398 
Blood samples collection. Blood samples from patients had been collected after recognition of a score 399 
of two or more (out of 4) clinical criteria for acute systemic inflammation, and immediately prior to antibiotic 400 
administration. Samples were collected in commercially available anticoagulant-treated tubes (K2 EDTA 401 
BD Vacutainer®). Plasma was then prepared by inverting the collection tubes to ensure mixing of blood 402 
with EDTA and subsequent centrifugation for 15 minutes at 1500x g at 4 0C. Following centrifugation, 403 
supernatant was immediately collected into labelled 1.5 mL screw-cap polypropylene tubes (Thermo 404 
Fisher), and samples were maintained on dry ice while handling. Finally, samples were stored in a -80 0C 405 
freezer and were thawed only before the incubations.  406 
For the ex vivo protein binding study of healthy controls, 6 female and 6 male human samples were 407 
supplied by Seralab, UK, Batches #BRH1401254 (H1), #BRH1401253 (H2), #BRH1401256 (H3), 408 
#BRH1401259 (H4), #BRH1401252 (H5), #BRH1401257 (H6), #BRH1401243 (H7), #BRH1401247 (H8), 409 
#BRH1401244 (H9), #BRH1401246 (H10), #BRH1401249 (H11) and #BRH1401248 (H12). Considering 410 
the impact of the anticoagulant agent on the formation of the protein corona,60 healthy plasma samples 411 
contained the same anticoagulant agent (K2 EDTA BD Vacutainer® tubes) as that described above for 412 
the human clinical samples and were subjected to the same preparation protocol (centrifugation for 12 min 413 
at 1300 rpm at 4 0C). Healthy human plasma samples were received on dry ice and were stored in a -80 414 
0C freezer upon arrival from Seralab, UK. Finally, samples were thawed only before the incubations.  415 
 416 
Preparation of AmBisome® liposomes suspension. 2 vials of AmBisome® liposomal formulation 417 
(HSPC:Cholesterol:DSPG:Amphotericin B, batch #006572D) were kindly donated by Salford Royal NHS 418 
Foundation Trust’s research and development team. 12 mL of HEPES buffer solution (HBS, 150 mM NaCl 419 
(Sigma Aldrich, S6191) and 20 mM HEPES (Sigma Aldrich, H3375), pH=7.4) were added to the vial and 420 
the reconstituted suspension was gently and thoroughly mixed. The concentration of liposomes in the 421 
reconstituted suspension was quantified by Stewart assay (see below) and was found to be ~41 mM. 422 
 423 
Ex vivo incubation of AmBisome® liposomes with human plasma. The ex vivo protein corona was 424 
allowed to form using AmBisome® liposomal formulation. AmBisome® was added into human plasma 425 
obtained from healthy individuals (n=12), non-infectious acute systemic inflammation (SIRS) patients 426 
(n=7) and sepsis patients (n=12). A concentration of 1 mM of liposomes (1 mM lipids/mL blood) was 427 
chosen for incubation based upon a dose of 3 mg of Amphotericin B/kg body weight.61, 62 Thus, 24 μL of 428 
AmBisome® were incubated with 820 μL of human plasma and 156 μL of HEPES buffer solution (HBS) to 429 
reach 1 mL volume for 1 hour at 37 0C in orbital shaker (ThermoFisher, MaxQ™ 4450 Benchtop Orbital 430 
Shaker) at 250 rpm, set to mimic in vivo conditions. 1 hour of ex vivo incubation was chosen because it is 431 
the equivalent time for the infusion of AmBisome®. 432 
 433 
Separation of corona-coated AmBisome® liposomes from unbound and weakly bound proteins. 434 
Corona-coated liposomes were separated form excess plasma proteins following a two-step purification 435 
protocol, including size exclusion chromatography and membrane ultrafiltration, as we have previously 436 




Size and zeta potential measurements using dynamic light scattering (DLS). The size and surface 439 
charge of AmBisome® liposomes were measured by Intensity using a Zetasizer Nano ZS (Malvern, 440 
Instruments, UK). For both size and ζ-potential measurements, samples were diluted with ultra-pure water 441 
in 1 mL polystyrene disposable cuvettes and 1 mL disposable Zetasizer cuvettes, respectively. Size and ζ-442 
potential data was taken in three records. 443 
 444 
Transmission Electron Microscopy (TEM). Liposomes were visualized with transmission electron 445 
microscopy (FEI Tecnai 12 BioTwin) before and after their ex vivo interaction with human plasma proteins. 446 
10 uL of each sample were diluted in 600 uL of ultra-pure water. A drop from each sample was placed 447 
onto a Carbon Film Mesh Copper Grid (CF400-Cu, Electron Microscopy Science) and subsequently was 448 
stained using aqueous uranyl acetate solution 1%.  449 
 450 
SDS-PAGE electrophoresis. Proteins associated with 0.025 μM of liposomes were loaded in 4-20% 451 
NovexTM Tris-Glycine Protein Gels (WedgeWellTM, ThermoFisher Scientific) along with a 10 – 180 kDa 452 
Prestained Protein Ladder (PageRulerTM Prestained Protein Ladder 10 – 180 kDa, ThermoFisher 453 
Scientific) and run through a 10 times diluted 10xNovexTM Tris-Glycine SDS Running Buffer 454 
(ThermoFisher Scientific) in ultra-pure water for 25-40 minutes at 225 V and 125 mA until the proteins 455 
reached the end of the gel. Gels were stained for 1 hour using the Imperial protein Gel Staining reagent 456 
(Imperial protein stain, ThermoFisher Scientific) followed by a couple of washings with ultra-pure water for 457 
1-2 days.  458 
 459 
Quantification of recovered lipids and adsorbed proteins. Lipid concentration (mM) was quantified by 460 
Stewart Assay using a Cary 50 Bio Spectrophotometer (Agilent Technologies), as we have previously 461 
described.18, 19, 21, 22 The total amount of the adsorbed proteins onto the surface of AmBisome® was 462 
quantified by BCA Protein assay kit (ThermoFisher Scientific), according to the manufacturer’s 463 
instructions, using a plate reader (Fluostar Omega plate reader, BMG Labtech). Protein binding (Pb) 464 
values, expressed as μg of protein/μmole of lipid were then calculated per patient and per group, 465 
presented as the average ± standard deviation (healthy controls n=12, SIRS patients n=7 and sepsis 466 
patients n=12). 467 
 468 
Mass Spectrometry. Corona proteins (20 μg) were loaded in 10 % NOVEX Tris-Glycine Protein Gels 469 
(WedgeWellTM, ThermoFisher Scientific) and run through a 10 times diluted 10xNovex® Tris-Glycine SDS 470 
Running Buffer (ThermoFisher Scientific) in ultra-pure water for 2-5 minutes at 225 V and 125 mA until the 471 
formation of a single band at the top of the gel. Gels were stained for 1 hour using the Imperial protein Gel 472 
Staining reagent (Sigma Life Science) followed by a couple of washings with ultra-pure water for 1-2 days. 473 
Gel bands were cut out in 1 mm small square pieces and placed into 96 perforated plate wells. Samples 474 
were reduced with 10 mM dithiothreitol, alkylated with 55 mM iodoacetamide, washed with ammonium 475 
bicarbonate and acetonitrile and digested by 12.5 ng/μL trypsin overnight at 37 0C. Following overnight 476 
incubation, samples were extracted using 20 mM ammonium bicarbonate and 50 % acetonitrile, 5 % 477 
formic acid, desalted and dried by vacuum centrifugation.  Dried samples were reconstituted in 10 μL 5 % 478 
acetonitrile 0.1 % formic acid and analyzed by LC-MS/MS using an UltiMate® 3000 Rapid Separation LC 479 
(RSLC, Dionex Corporation, Sunnyvale, CA) coupled to a Q Exactive™ Hybrid Quadrupole-Orbitrap™ 480 
(ThermoFisher Scientific, Waltham, MA) mass spectrometer.  481 
 482 
Mass Spectrometry Data Analysis. RAW files were imported into Progenesis LC-MS software (version 483 
3.0; Nonlinear Dynamics) with automatic feature detection enabled. A representative reference run was 484 
selected automatically to which all other runs were aligned in a pair-wise manner. Automatic processing 485 
was selected to run with applied filters for peaks charge state (maximum charge 5) and protein 486 
quantitation method the relative quantitation using Hi-N with N=3 peptides to measure per protein. The 487 
resulting MS/MS peak lists were exported as a single Mascot generic file and loaded onto a local Mascot 488 
Server (Matrix Science, London, UK; version 2.5.1). The spectra were searched against the 489 
SwissProt_2018_01 database (selected for Homo sapiens, 161629 entries) using the following 490 
parameters: tryptic enzyme digestion with one missed cleavage allowed, peptide charge of +2 and +3, 491 
precursor mass tolerance of 15 mmu, fragment mass tolerance of 8 ppm, oxidation of methionines as 492 
variable modifications and carbamidomethyl as fixed modifications, with decoy database search disabled 493 
15 
 
and ESI-QUAD-TOF the selected instrument. Each search produced an XML file from Mascot and the 494 
resulted peptides (XML files) were imported back into Progenesis LC-MS to assign peptides to features. 495 
Data was filtered to present a score above 21 through the ‘refine identification’ tab of Progenesis QI 496 
toolbox. A table of all identified features along with their normalized peptide and protein abundance in 497 
each sample was generated. The max fold-change and p value (ANOVA) of each protein was then 498 
calculated by Progenesis and data including the normalized abundance, p-value and max fold-change 499 
were exported for further analysis. Finally, results were filtered to present a mean normalized abundance 500 
of more than 50,000 in at least one of the three groups. 501 
Mass Spectrometry data was further analyzed through the use of QIAGEN’s Ingenuity Pathway Analysis® 502 
(IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity). Diseases and functions IPA tool was used to 503 
identify proteins involved in inflammation and bacterial infection pathways. The biomarker overlay IPA tool 504 
was then used to identify proteins described in the literature as potential systemic inflammatory response 505 
and sepsis biomarkers for diagnosis, efficacy or any unspecified application.  506 
 507 
Enzyme-linked Immunosorbent Assay (ELISA). Sandwich-ELISA kits for the human proteins CRP 508 
(CRP, ab99995, Abcam, UK), serum amyloid P (APCS, ab137970, Abcam, UK) and cathepsin G (CTSG, 509 
abx251221, Abbexa Ltd, UK) were purchased for the quantitative measurement of each corona protein in 510 
plasma. Experiments were performed according to manufacturer’s instructions. All assays employed an 511 
antibody specific for each human protein coated on a 96-well plate. Standards and samples were pipetted 512 
into the wells and protein present in a sample was bound to the wells by the immobilized antibody. The 513 
wells were then washed and biotinylated anti-human protein antibody was added. After washing away 514 
unbound biotinylated antibody, HRP-conjugated Streptavidin was pipetted to the wells. Following a 515 
second washing, a TMB substrate solution was added to each well to allow colour development in 516 
proportion to the amount of each bound protein. Finally, stop solution was added to the wells, colour 517 
changed from blue to yellow and the absorbance was measured at 450 nm using a plate reader (Fluostar 518 
Omega plate reader, BMG Labtech). A standard curve was prepared based upon the intensity of the 519 
colour of the standard solutions by GraphPad Prism 7 regression analysis and the concentration of the 520 
bound protein per sample was calculated. 521 
 522 
Statistical analysis. Statistical analysis of the data was performed using GraphPad Prism 7 software. 523 
The non-parametric Kruskal-Wallis tests was used and p values<0.05 were considered significant. 524 
Receiver operating curves (ROC) and the respective Area under the Curve (AUC) values were produced 525 
and calculated based on the ELISA data of each selected for validation protein using GraphPad Prism 7 526 
software (Figure S3). 527 
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FIGURE LEGENDS 549 
 550 
Figure 1: Physicochemical characterization of corona-coated Amphotericin B-intercalated liposomes 551 
(AmBisome®). (A) Schematic description of the experimental design. Liposomes were incubated ex vivo (1 hour at 552 
370C, 250 rpm) with human plasma samples obtained from a) healthy donors (n=12), b) SIRS patients (n=7) and c) 553 
sepsis patients (n=12). Ex vivo corona-coated liposomes were recovered and purified from unbound proteins and the 554 
formed protein coronas were qualitatively and quantitatively characterised and compared between the groups; (B) 555 
Mean hydrodynamic diameter (nm) and ζ-potential (mV) distributions for the liposomal formulation AmBisome®, 556 
before and after ex vivo incubation with human plasma. Table shows the average mean hydrodynamic diameter (nm), 557 
polydispersity index (PDI) and ζ-potential (mV) values of bare and corona-coated liposomes; (C) Negative stain TEM 558 
imaging of bare and corona-coated AmBisome® liposomes, recovered post-incubation with human plasma obtained 559 
from healthy controls, SIRS patients and sepsis patients. All scale bars are 100 nm.  560 
 561 
Figure 2: Quantitative and qualitative comparison of the ex vivo protein coronas formed onto AmBisome® 562 
liposomes. (A) Comparison of the total amount of protein adsorbed onto liposomes after their ex vivo incubation with 563 
plasma obtained from healthy donors (n=12), SIRS patients (n=7) and sepsis patients (n=12), (expressed as μg 564 
protein/μmole of NP). Pb values represent the average and standard error. ** indicates p<0.01 (p=0.0068) between 565 
healthy donors and sepsis patients using the non-parametric Kruskal-Wallis test; (B) Imperial stained SDS-PAGE gels 566 
of plasma control and corona proteins associated with liposomes after incubation with plasma obtained from healthy 567 
donors, SIRS patients and sepsis patients. 568 
 569 
Figure 3: The NP protein corona-enabled biomarker discovery to differentiate sepsis from non-infectious 570 
acute systemic inflammation. (A) Heatmap of normalized abundance values of corona proteins differentially 571 
abundant between SIRS controls and sepsis patients, after identification by LC-MS/MS and data analysis by 572 
Progenesis QI. Protein columns are sorted according to the abundance values (from highest to lowest) of the first 573 
sample. The list of proteins shown in the heatmap and their respective accession numbers, p-values and max fold-574 
change are shown in Table S4; (B) Volcano plot represents the potential protein biomarkers differentially abundant 575 
between sepsis group and SIRS control group (n=67) identified in corona samples. Upregulated biomarkers in sepsis 576 
group are shown in red (n=34), whereas downregulated biomarkers in the presence of sepsis are shown in blue 577 
colour (n=33). Only proteins with p value<0.05 are reported. The list of proteins shown in the volcano plot and their 578 
respective accession numbers, p-values and max fold-change are shown in Table 1; (C) Ingenuity Pathway Analysis 579 
(IPA) of potential biomarker corona proteins associated with bacterial infection. The name of proteins illustrated in the 580 








































































Table 1: Candidate corona protein biomarkers for differentiating between sepsis and non-infectious acute 645 
systemic inflammation patients, as identified by proteomic analysis of the ex vivo liposome coronas. Full list of 646 
proteins identified by Progenesis QI for proteomics to be upregulated or downregulated in sepsis patients in comparison 647 
with SIRS controls classified from the highest max fold-change to the lowest. Only proteins with p<0.05 are shown. 648 
 649 








OTU domain-containing protein 7A OTU7A_HUMAN 4.32E-03 13.23 
Immunoglobulin kappa variable 1D-13 KVD13_HUMAN 4.34E-03 10.14 
Dual specificity mitogen-activated protein 
kinase kinase 7 
MP2K7_HUMAN 4.60E-02 4.11 
NEDD4-binding protein 2 N4BP2_HUMAN 4.11E-03 3.19 
Complement component C8 gamma chain CO8G_HUMAN 1.68E-03 3.07 
Sentrin-specific protease 2 SENP2_HUMAN 7.28E-03 2.88 
Ficolin-2 FCN2_HUMAN 2.92E-05 2.79 
Fibulin-1 FBLN1_HUMAN 2.62E-03 2.64 
Endophilin-A3 SH3G3_HUMAN 4.97E-02 2.64 
Sorting nexin-32 SNX32_HUMAN 4.75E-02 2.64 
Immunoglobulin heavy constant gamma 2 IGHG2_HUMAN 3.75E-02 2.44 
Complement component C7 CO7_HUMAN 1.29E-03 2.36 
Immunoglobulin gamma-1 heavy chain IGG1_HUMAN 2.69E-02 2.31 
Immunoglobulin heavy constant gamma 3 IGHG3_HUMAN 4.21E-02 2.28 
Unconventional myosin-XV MYO15_HUMAN 4.77E-02 2.22 
Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4_HUMAN 3.59E-03 2.14 
Complement C5 CO5_HUMAN 2.49E-03 2.12 
Hemoglobin subunit alpha HBA_HUMAN 7.97E-03 2.04 
Complement component C6 CO6_HUMAN 1.72E-02 2.00 
Complement component C8 beta chain CO8B_HUMAN 3.47E-02 1.94 
Synapsin-3 SYN3_HUMAN 3.89E-02 1.91 
Hemoglobin subunit delta HBD_HUMAN 1.36E-02 1.90 
Inter-alpha-trypsin inhibitor heavy chain H3 ITIH3_HUMAN 3.51E-02 1.90 
Complement factor H-related protein 1 FHR1_HUMAN 1.64E-02 1.89 
Lipopolysaccharide-binding protein LBP_HUMAN 4.48E-02 1.86 
FANCD2 opposite strand protein FACOS_HUMAN 3.76E-02 1.85 
Complement C3 CO3_HUMAN 1.77E-02 1.85 
Fibrinogen alpha chain FIBA_HUMAN 1.59E-02 1.78 
Histone H2B type 1-A H2B1A_HUMAN 1.70E-02 1.70 
Serum amyloid P-component SAMP_HUMAN 3.12E-02 1.68 
Carboxypeptidase N catalytic chain CBPN_HUMAN 3.98E-02 1.66 
Complement factor H CFAH_HUMAN 3.87E-02 1.53 
Hemoglobin subunit beta HBB_HUMAN 2.69E-02 1.48 
Vitronectin VTNC_HUMAN 4.17E-02 1.38 








N-terminal EF-hand calcium-binding protein 2 NECA2_HUMAN 1.02E-03 317.68 
Flotillin-2 FLOT2_HUMAN 2.27E-02 18.41 
Dematin DEMA_HUMAN 4.38E-02 11.90 
B-cell lymphoma/leukemia 10 BCL10_HUMAN 1.86E-02 6.11 
ATP-dependent 6-phosphofructokinase, liver 
type 
PFKAL_HUMAN 7.88E-03 3.56 
Cancer-associated gene 1 protein CAGE1_HUMAN 2.04E-02 3.51 
Ras-related protein Ral-B RALB_HUMAN 3.18E-02 3.17 
Immunoglobulin lambda variable 1-44 LV144_HUMAN 1.26E-02 3.05 
Guanine nucleotide-binding protein G(i) 
subunit alpha-2 
GNAI2_HUMAN 8.28E-04 2.96 
Cytoplasmic dynein 1 heavy chain 1 DYHC1_HUMAN 3.24E-02 2.86 
Immunoglobulin kappa variable 1-12 KV112_HUMAN 2.64E-02 2.65 
Aminopeptidase N AMPN_HUMAN 4.48E-02 2.59 
Tenascin-X TENX_HUMAN 7.46E-04 2.54 
Immunoglobulin heavy variable 3-48 HV348_HUMAN 4.13E-02 2.51 
Immunoglobulin kappa variable 1-17 KV117_HUMAN 9.46E-03 2.40 
Ubiquitin-40S ribosomal protein S27a RS27A_HUMAN 5.41E-05 2.17 
Gamma-aminobutyric acid receptor subunit 
alpha-1  
GBRA1_HUMAN 1.98E-02 2.16 
Serine/arginine-rich splicing factor 4 SRSF4_HUMAN 2.50E-02 2.11 
Immunoglobulin heavy variable 6-1 HV601_HUMAN 1.65E-02 2.08 
Annexin A2 ANXA2_HUMAN 2.84E-02 2.04 
Sulfhydryl oxidase 2 QSOX2_HUMAN 2.70E-02 2.03 
PI-PLC X domain-containing protein 2 PLCX2_HUMAN 1.23E-02 1.99 
Immunoglobulin kappa variable 1-5 KV105_HUMAN 3.97E-02 1.99 
Immunoglobulin heavy variable 3-23 HV323_HUMAN 3.20E-02 1.96 
Immunoglobulin kappa variable 2-24 KV224_HUMAN 3.17E-02 1.90 
Immunoglobulin lambda variable 2-11 LV211_HUMAN 3.28E-02 1.90 
Desmoglein-1 DSG1_HUMAN 2.90E-02 1.79 
Immunoglobulin lambda variable 1-51 LV151_HUMAN 2.88E-02 1.73 
CD5 antigen-like CD5L_HUMAN 4.63E-02 1.72 
Immunoglobulin kappa variable 3-11 KV311_HUMAN 2.28E-02 1.69 
Apolipoprotein L1 APOL1_HUMAN 4.15E-02 1.62 
Oxysterol-binding protein-related protein 11 OSB11_HUMAN 3.70E-02 1.60 
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